A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial

Julian Biau (1, 2) , Emilie Thivat (2) , Corinne Millardet , Nicolas Saroul , Nathalie Pham-Dang , Ioana Molnar (1, 2) , Bruno Pereira , Xavier Durando (2, 1) , Jean Bourhis , Michel Lapeyre

1 IMoST - Imagerie Moléculaire et Stratégies Théranostiques
2 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]

Primary surgery is usually the mainstay treatment in early-stage oropharyngeal and oral cavity cancer. Typically, neck surgery is performed. Negative tumor margins are recommended (> 5 mm). If feasible, re-resection of any positive margin is preferred. Otherwise, postoperative radiotherapy is required. Adjuvant postoperative radiotherapy can be limited to the primary site for patients with pT1-T2 tumors and negative neck exploration. Currently, both fractionated external beam radiotherapy and brachytherapy can have a role in the postoperative management of early-stage oropharyngeal and oral cavity cancer with high risk margins. Another possible alternative could be postoperative stereotactic body radiotherapy (SBRT). The aim of this study is to evaluate postoperative SBRT in the treatment of early-stage oropharyngeal and oral cavity cancer with high risk margins.

Mots clés: Hypofractionated stereotactic body radiotherapy (SBRT); Oropharyngeal and Oral cavity cancers; Postoperative radiotherapy

Domaines: Sciences du Vivant [q-bio]; Cancer

Julian Biau, Emilie Thivat, Corinne Millardet, Nicolas Saroul, Nathalie Pham-Dang, et al.. A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial. BMC Cancer, 2020, 20 (1), pp.730. ⟨10.1186/s12885-020-07231-3⟩. ⟨hal-03052704⟩